ADAM BRASKET: Open Payments
NPI 1467072132 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,436 in 75 payments from 11 companies in 2025. Trend: 2023 $1,032 · 2024 $645 · 2025 $1,436
Food & beverage: $1,436
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $316 |
| E.R. Squibb & Sons, L.L.C. | 19 | $293 |
| Neurocrine BioSciences, Inc. | 10 | $232 |
| Teva Pharmaceuticals USA, Inc. | 9 | $158 |
| Otsuka America Pharmaceutical, Inc. | 5 | $123 |
| Janssen Pharmaceuticals, Inc | 5 | $112 |
| Alkermes, Inc. | 4 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
Products named: VRAYLAR, COBENFY, INGREZZA, AUSTEDO XR, VIVITROL, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across CA — which companies pay providers there.
